Updated:
Progyny
Progyny runs a fertility benefits platform covering over 5 million lives for employers like Google and Microsoft.
Progyny
Founded in 2008, Progyny was built by a team that experienced fertility challenges firsthand, with CEO David Schlanger later joining to scale the company from a startup to a publicly traded entity. The firm does not manage financial assets in the traditional sense; its capital is deployed into building a proprietary benefits platform that covers fertility, egg freezing, adoption, and surrogacy services for large self-insured employers. Progyny's strategy centers on bundling clinical network management, patient concierge support, and data-driven outcomes tracking. The company contracts with top-tier fertility clinics and reproductive endocrinologists across the United States, offering members a single point of access. Its employer client list has included names like Google, Microsoft, and Meta, covering over 440 employer clients as of its 2023 annual filing. Deployment is concentrated in North America, where employer-sponsored health plans drive demand. As a publicly traded company (NASDAQ: PGNY), Progyny has scaled its team to support national operations from its New York City headquarters. The firm reported over $1 billion in revenue for the full year 2023, reflecting its position as a dominant administrator in the fertility benefits niche. In early 2024, Progyny expanded its family-building platform to include dedicated menopause and women's health care pathways, signaling a broader scope beyond fertility. Progyny's structural differentiator is its closed-network, outcomes-based model. Unlike broad insurance carriers that add fertility riders, Progyny operates a managed care network that ties reimbursement to single-embryo transfer rates and healthy deliveries, not per-service volume — a contractual architecture that aligns clinic incentives with patient health outcomes rather than treatment volume.
General information
Firm type
Asset Manager
Year founded
2008
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
David Schlanger
Chief Executive Officer
Peter Anevski
President
Sector focus
Frequently asked questions
How does Progyny source its network of fertility clinics?
Progyny uses a selective contracting process, evaluating clinics on outcomes data including single-embryo transfer rates and live birth success. Clinics must agree to bundled-pricing models and integrate with Progyny's patient-navigation platform.
Is Progyny's model more aligned with a health insurer or a benefits administrator?
It functions as a specialized benefits administrator managing a narrow network. Progyny is not an insurer; it does not bear underwriting risk. Instead, self-insured employers pay per-member-per-month fees and treatment- cycle fees that Progyny passes through to contracted clinics under pre-negotiated rates.
What differentiates Progyny's clinical approach from standard fertility insurance riders?
The key difference is the 'SmartCycle' bundling. Instead of a dollar cap, a SmartCycle covers an entire episode — diagnostics, retrieval, genetic testing if indicated, and a single embryo transfer — incentivizing clinics to prioritize a live birth on the first transfer rather than multiple attempts.
Who are Progyny's major publicly disclosed employer clients?
The company's marketing materials and Securities and Exchange Commission filings have referenced large technology-sector clients. Publicly known names include Google, Meta, and Microsoft, though the full client roster is not individually listed by the firm.
How is Progyny managed, and who holds day-to-day operational control?
David Schlanger serves as CEO, having taken the role after leading Progyny through its 2019 initial public offering. Peter Anevski, President, oversees client-facing operations and growth. The founders remain significant shareholders and board contributors but are not in daily executive roles.
What are Progyny's recent areas of geographic or service expansion?
Operations remain focused on the United States. In early 2024 the company introduced menopause and women's midlife health care pathways, extending its women's health continuum beyond reproductive-age fertility to perimenopausal and menopausal support.
Is Progyny public, and what is its ownership structure?
Progyny trades on NASDAQ under ticker PGNY, having priced its initial public offering in October 2019. It is a widely held public company with institutional shareholders and no controlling family-wealth concentration.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: